Possible scenario
Broad Lab Adoption
42% Chance
US academic, hospital, and government labs take up the free life-sciences program because it lowers the cost of literature review, assay design, protocol drafting, and data interpretation. The most likely path is a controlled rollout with compliance tooling rather than unrestricted model access.
Secondary impacts
- Technology +0.6%
- Healthcare +0.5%
- Business Services +0.2%
Tickers
- NVDA+0.8%
- MSFT+0.6%
- MRNA+0.4%
Portfolio impact
S&P 500+0.3%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.